Raltegravir: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Changed protection level for "Raltegravir" ([Edit=Allow only autoconfirmed users] (expires 14:48, 16 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 14:48, 16 January 2014 (UTC))))
No edit summary
Line 1: Line 1:
{{drugbox
__NOTOC__
| IUPAC_name =
{{Raltegravir}}
| image = Mk-0518.png 
{{CMG}}; {{AE}} {{chetan}}
| CAS_number = 871038-72-1
| ATC_prefix =
| ATC_suffix =
| ATC_supplemental =
| PubChem =
| DrugBank =
| C=20 | H=21 | F=1 | N=6 | O=5
| molecular_weight = 444.42
| bioavailability = "good"
| protein_bound = 
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_category =
| legal_status =
| routes_of_administration = oral }}
[[Image:Isentress_pilules.png|thumb|Isentress pills]]


'''Raltegravir''' (MK-0518, brand name ''Isentress''<sup>TM</sup>) is an experimental [[antiretroviral drug]] from [[Merck & Co]]. It is the first to enter Phase III clinical trials in the [[integrase inhibitor]] class. It targets [[integrase]], an enzyme that HIV uses to integrate its genetic material into human cells.  Raltegravir, and other integrase inhibitors, are often termed strand transfer inhibitors.  This refers to the process of DNA strand transfer from the viral genome to the host genome.
==Overview==


During [[2006]], the drug entered Phase III [[clinical trial]]s, and it is available to certain patients with advanced HIV disease through an expanded access program. [http://www.earmrk.com/]
==Category==


Raltegravir is taken orally twice daily. Doses of 200, 400, and 600 mg have been studied.
==US Brand Names==


At the 2007 Conference on Retroviruses and Opportunistic Infections, researchers presented Phase III data showing that 77% of patients taking the 400 mg dose of raltegravir plus other antiretroviral drugs reached HIV viral loads below 400 copies, nearly twice as many compared with a control group.
==FDA Package Insert==


On September 5, 2007, the FDA's Advisory Committee unanimously recommended the accelerated approval of Isentress. 
'''  [[Raltegravir description|Description]]'''
'''| [[Raltegravir clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Raltegravir microbiology|Microbiology]]'''
'''| [[Raltegravir indications and usage|Indications and Usage]]'''
'''| [[Raltegravir contraindications|Contraindications]]'''
'''| [[Raltegravir warnings and precautions|Warnings and Precautions]]'''
'''| [[Raltegravir adverse reactions|Adverse Reactions]]'''
'''| [[Raltegravir drug interactions|Drug Interactions]]'''
'''| [[Raltegravir overdosage|Overdosage]]'''
'''| [[Raltegravir clinical studies|Clinical Studies]]'''
'''| [[Raltegravir dosage and administration|Dosage and Administration]]'''
'''| [[Raltegravir how supplied|How Supplied]]'''
'''| [[Raltegravir labels and packages|Labels and Packages]]'''
 
==Mechanism of Action==


==References==
==References==
*Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs. 2006 Dec;15(12):1507-22. [http://www.ingentaconnect.com/content/apl/eid/2006/00000015/00000012/art00004?token=00461400d664264f65263a3d4f58762f467c405847447b23442f5f31256f5b20655d3b]
{{Reflist|2}}
 
==External links==
* [http://www.aidsmeds.com/drugs/MK-0518.htm MK-0518 at Aidsmedscom]
* [http://www.aidsmap.com/en/news/D8457D0C-2A61-4436-B416-B9627821E50C.asp Integrase Inhibitor Raltegravir (MK-0518) Doubles HIV Suppression in Treatment-Experienced Patients (Aidsmap 28 February 2007)]
* [http://www.retroconference.org/2007/Abstracts/30687.htm RMK-0518 Abstract from CROI 2007]
* [http://www.medicalnewstoday.com/medicalnews.php?newsid=37591 Interim Results From Phase II Study Of MK-0518]
* [http://www.wipo.int/pctdb/en/wo.jsp?wo=2006060712 World patent covering the potassium salt]
 
 
{{antimicrobial-stub}}
 
[[Category:Antiretroviral drugs]]


[[fr:Raltegravir]]
[[Category:Antibiotics]]
{{WikiDoc Help Menu}}
[[Category:Wikinfect]]
{{WikiDoc Sources}}

Revision as of 00:00, 10 January 2014

Raltegravir
Isentress® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Overview

Category

US Brand Names

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages

Mechanism of Action

References

Retrieved from "https://www.wikidoc.org/index.php?title=Raltegravir&oldid=931088"